Acute Physiological Effects of Electronic Sigarette vs Cigarette Smoking
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02102191 |
Recruitment Status :
Completed
First Posted : April 2, 2014
Last Update Posted : October 7, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Because e-cigarettes do not contain or burn tobacco, they do not appear to deliver the known toxins found in conventional cigarette smoke.However e-Cigarettes with low dose of tobacco were found to have immediate adverse physiologic effects after short-term use that are similar to some of the effects seen with tobacco smoking.
In this study we wanted to assess the short-time effect of one e-cigarette with no tobacco vs a "traditional" cigarette.
10 n-smoking subject and 10 actual smokers will be enrolled in the randomized trial.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Individuality | Device: e-cigarette Device: cigarette | Not Applicable |
On day 1 the subjects will be asked to smoke either the e-cigarette or a "traditional" one for 5 minutes. On day 2 the subject will be ask to smoke for 5 minutes the other kind of cigarette.
Exhaled Nitric Oxide will be measured in a sitting position with a nose clip using an analyzer equipped with a software program. The patient will be instructed to inhale as deeply as possible to total lung capacity through a filter mouthpiece and consecutively exhale at a mouth fl ow rate of 50 mL/s for 10 s. Three consecutive trials will be performed with a 30-s interval.
Dynamic Lung Volumes: Flows and lung volumes will be measured in the sitting position, a spirometry system (heated pneumotach, with the highest FEV 1 recorded in line with pulmonary guidelines. Spirometry will be measured according to the recommendations of the American Thoracic Society/European Respiratory Society task force guidelines. FEV 1, FVC, FEV 1 %, peak expiratory fl ow (PEF), and maximal expiratory fl ow (MEF) at 25%, 50%, and 75% of vital capacity will be measured. Each maneuver will be repeated for at least three technically acceptable forced expiratory fl ow curves.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | Acute Physiological Effects of Electronic Sigarette vs Cigarette Smoking: a RCT |
Study Start Date : | March 2014 |
Actual Primary Completion Date : | October 2014 |
Actual Study Completion Date : | October 2014 |

Arm | Intervention/treatment |
---|---|
Active Comparator: cigarette
common cigarette sold in the stores
|
Device: e-cigarette
smoking cigarette without tobacco Device: cigarette smoking cigarette with tobacco |
Active Comparator: e-cigarette
e-cigarette (Ovale Elips)
|
Device: e-cigarette
smoking cigarette without tobacco Device: cigarette smoking cigarette with tobacco |
- spirometric data [ Time Frame: five minutes ]
- nitric oxyde level [ Time Frame: 5 minutes ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 10 no smoking healthy individuals
- 10 smoking (>20 pack/yr) healthy individuals
Exclusion Criteria:
- pre-existing diseases
- FEV1/FVC ratio<70%

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02102191
Italy | |
Fondazione Salvatore Maugeri | |
Pavia, Province, Italy, 27100 |
Study Chair: | stefano nava, md | AO Sant'Orsola |
Responsible Party: | dr. Stefano Nava, professor of respiratory disease, IRCCS Azienda Ospedaliero-Universitaria di Bologna |
ClinicalTrials.gov Identifier: | NCT02102191 |
Other Study ID Numbers: |
972CE 23 ( Other Identifier: SIME ) |
First Posted: | April 2, 2014 Key Record Dates |
Last Update Posted: | October 7, 2014 |
Last Verified: | October 2014 |